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organs-at-risk toxicity. This study was performed to assess 
the best dosimetric predictor of urethra strictures. 
Materials and Methods: Patients treated between 2001 and 
2013 at a single institution with HDRB were retrospectively 
analysed. The patients were all reviewed 6, 12, 18, 24 
months and then every year until 10 years after the 
treatment and data collected in a database. Clinical, 
demographic, dosimetric and urethral stricture factors were 
captured. We used urethra Dose Volume Histograms (DVH) 
metrics: D10% (Gy), D5%(Gy) and D30%(Gy). We converted 
doses from 3 different fractionation regimes (18 Gy in 3, 19 
Gy in 2 and 18 Gy in 2 fractions) into Biological Effective Dose 
(BED) with α/β = 5 Gy. Univariate and Multivariate logistic 
regression were used to evaluate factors predictive of 
urethral stricture after HDRB. 
Results: 
 
We analysed data from 249 patients, with a median follow-up 
of 7 years (1.4- 13.4 years). Urethra strictures were present 
in 25/249 (10%) patients, and the median time to onset 
stricture was about 1.5 years (1 month-7 years). 
On univariate analysis, BED10%(Gy) (OR = 1.05, p= 0.01), 
BED30%(Gy) (OR = 1.05, p= 0.02), and BED5%(Gy) (OR=1.05, 
p= 0.01) were significantly correlated to urethra stricture. 
The AUC of the resulting model was 0.62 in all cases, 
however calibration was always suboptimal. Calibration 
showed improvement when the dosimetric factors were 
associated to clinical factors despite their lower significance, 
such as use of neoadjuvant androgen deprivation (OR=0.5, 
protective factor) which was present in 232 patients (Figure 
1).  
Conclusions: Urethra DVH metrics are related to stricture, 
particularly the dose to small urethra volumes (D10%). 
However androgen deprivation acts as an important dose 
response modifier, pointing out the importance of integrating 
dosimetric and clinical information in order to have a better 
identification of the subgroup of patients at high risk of 
developing severe urinary toxicity after HDRB. 
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Purpose/Objective: To demonstrate the feasibility, safety 
and effectiveness of dose escalation to Dominant 
Intraprostatic Lesion (DIL) as defined on multiparametric MRI 
(mpMRI) with Real-Time MRI-TRUS fusion High-Dose-Rate 
(HDR) Brachytherapy 
Materials and Methods: 15 patients with intermediate-high 
risk Prostate cancer and visible dominant intra-prostatic 
nodule on mpMRI have been treated prospectively. The 
treatment consisted of combined MRI-TRUS fusion HDR-
brachytherapy (1 fraction of 1500 cGy) and Hypofractionated 
external beam (3750 cGy in 15 fractions) (BED: 265Gy). 
Prostate gland, DILs and Organs at risk (OARs) were 
delineated on MRI dataset, MRI-TRUS fusion performed and 
contoured structures transferred to the US dataset. 
The homogeneity parameters used for optimization aim were 
prostate-V100 > 98%, V150 of 25-33%, V200 < 8%, urethral 
Dmax < 115% and rectal D1cc < 70% of prescribed dose. 
Within these constraints, a dose of 1875 Gy was delivered to 
at least 98% of the DIL volume (V125%>98%)(BED: 351Gy) 
Results: Median age was 70 years, median prostate volume 
was 23.8 cc, median number of needles was 16 (13-18). Dose 
escalation to DIL was feasible in 14/15 patients (93%) without 
violating dosimetric constraints and 1 patient presented a 
minimal deviation of dosimetric restrictions. Median prostate 
V100, V150 and V200 were 98.2, 30.6 and 7.4% respectively. 
Median urethral Dmax was 114.1%, median rectal D1cc was 
62.8%. Median V100, V125, V150 and V200 to DIL were: 100, 
99, 78.5 and 20% respectively. 
With a median follow-up of 10 months (range 9-16), none of 
the patients developed acute urinary retention, only 2 
patients presented acute GU grade 2 toxicity, none of the 
patients developed chronic grade ≥2 toxicity. All patients 
returned to the pre-treatment IPSS level after 2 months of 
follow-up. 
In addition to standard PSA follow-up, response has been 
assessed by mpMRI at 12 months. All patients evaluated with 
MRI presented a complete response based on functional 
parameters. 
Conclusions: This study demonstrates that dose escalation to 
DIL with MRI/TRUS fusion guided HDR brachytherapy is 
feasible, longer follow-up will demonstrate the safety and 
efficacy of this procedure. 
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Purpose/Objective: External Beam Radiotherapy (EBRT) is 
considered the standard practice for localized prostate 
cancer. Although this, local relapses are not negligible and 
the ideal salvage treatment is not well-defined. We report 
our outcomes in terms of efficacy and safety of Salvage High-
Dose-Rate Brachytherapy (HDRB) for locally recurrent 
prostate cancer after definitive radiation therapy (RT). 
Materials and Methods: From august 2004 to July 2014 we 
retrospectively analyzed 60 patients (pts) undergoing HDR-BT 
after pathologic confirmation of locally recurrent disease. 
The median age at recurrence was 66 years (55-77) and, the 
median PSA was 4’13ng/ml (1’27-17). Gleason score and T 
scale were 7 and T2, respectively. Prescribed total dose was 
38Gy. Pts received 4 fractions of 9’5Gy with 2 implants 
separated 2 weeks. The 6% of pts received neoadjuvant 
hormonotherapy and, 11% received adjuvant hormonal 
